CSBR (Champions Oncology) Common Stock: $0.01 Mil (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $5.76
GF Value $6.64
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Common Stock?

Champions Oncology CSBR -4.71% 64 Common Stock is $0.01 Mil as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.64 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Champions Oncology's quarterly common stock stayed the same from Jul. 2025 ($0.01 Mil) to Oct. 2025 ($0.01 Mil) and stayed the same from Oct. 2025 ($0.01 Mil) to Jan. 2026 ($0.01 Mil).

Champions Oncology's annual common stock stayed the same from Apr. 2023 ($0.01 Mil) to Apr. 2024 ($0.01 Mil) and stayed the same from Apr. 2024 ($0.01 Mil) to Apr. 2025 ($0.01 Mil).

Champions Oncology Common Stock Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Common Stock Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
CSBR
64GF Score
Champions Oncology Inc CSBR
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Champions Oncology (CSBR) has a Common Stock of $0.01 Mil as of Jan. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Common Stock too high?
Champions Oncology's current Common Stock is $0.01 Mil. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Common Stock compare to SEER and RLYB?
Champions Oncology's Common Stock of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Champions Oncology and its competitors. Champions Oncology's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.64, compared to a current price of $5.76 — trading 13.3% below its estimated fair value. The current Common Stock is $0.01 Mil. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Common Stock is $0.01 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $5.76 is trading 13.3% below its estimated GF Value™ of $6.64. GuruFocus considers Champions Oncology to be Modestly Undervalued.

Key valuation signals for CSBR:

  • Common Stock: $0.01 Mil
  • GF Value™: $6.64 vs. price of $5.76 (13.3% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.76
Price
$6.64
GF Value